Armata Pharmaceuticals, Inc. (ARMP) Key Metrics
ARMP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $125.3M
- Enterprise value
- $446.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 22.6 10-yr median 29.5
- Price / book
- 2.1 10-yr median 2.2
- EV / EBITDA
- 14.4
- Dividend yield
- —
- Beta
- 1.41
ARMP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsARMP valuation Price multiples at each fiscal year-end price.
Price / sales+258.9%
46.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+47.4 pts
−11.6%
2025 · hover or tap a bar for each year
20162025
ARMP returns How much profit the business earns on the capital it uses.
Return on invested capital+8.6 pts
−38.0%
2025 · hover or tap a bar for each year
20162025
Return on assets−192.4 pts
−212.8%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+225.7 pts
−536.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover+7.2%
0.06
2025 · hover or tap a bar for each year
20162025
ARMP per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−5.4%
$0.14
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$4.80
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.73
2025 · hover or tap a bar for each year
20162025
Book value per share
−$6.03
2025 · hover or tap a bar for each year
20162025
Shares outstanding+0.2%
36.2M
2025 · hover or tap a bar for each year
20162025
ARMP financial health Debt, liquidity and how easily interest is covered.
Net debt+$162.1M
$279.3M
2025 · hover or tap a bar for each year
20162025
Current ratio+408.8%
1.19
2025 · hover or tap a bar for each year
20162025
Interest coverage
-1.9
2025 · hover or tap a bar for each year
20162025
Debt / assets+155.9%
3.75
2025 · hover or tap a bar for each year
20162025
ARMP efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−100 days
45 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+189 days
201 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−288 days
-156 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−25.3 pts
11.1%
2025 · hover or tap a bar for each year
20162025
ARMP valuation history
Fiscal year-endToday10-year median
ARMP returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ARMP debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ARMP cash returned to shareholders
DividendsBuybacksFree cash flow
ARMP price vs earnings per share
Share price at year-endEPS (right axis)
ARMP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $227.6M | $66.9M | $116.9M | $42.5M | $132.1M | $48.9M | $25.4M | — | — | — |
| Enterprise value | $506.9M | $184.1M | $223.7M | $76.5M | $159.8M | $52.4M | $22.3M | — | — | — |
| Price / sales | 46.4 | 12.9 | 25.8 | 7.7 | 29.5 | 59.4 | 820.6 | — | — | — |
| Price / book | — | — | — | 1.2 | 5.2 | 2.6 | 1.7 | — | — | — |
| EV / sales | 103.4 | 35.6 | 49.4 | 13.9 | 35.7 | 63.7 | 718.3 | — | — | — |
| Earnings yield | −76.4% | −28.3% | −59.1% | −86.8% | −17.5% | −45.3% | −76.6% | — | — | — |
| Free cash flow yield | −11.6% | −58.9% | −47.5% | −81.6% | −18.8% | −39.0% | −61.8% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $6.28 | $1.85 | $3.24 | $1.24 | $5.48 | $2.98 | $3.25 | $2.94 | $14.14 | $61.60 |
| Per share | ||||||||||
| Revenue per share | $0.14 | $0.14 | $0.13 | $0.16 | $0.19 | $0.05 | $0.00 | — | — | — |
| Earnings per share | −$4.80 | −$0.52 | −$1.91 | −$1.08 | −$0.96 | −$1.35 | −$2.49 | — | — | — |
| Operating cash flow per share | −$0.71 | −$1.04 | −$1.31 | −$0.95 | −$0.98 | −$1.11 | −$1.99 | — | — | — |
| Free cash flow per share | −$0.73 | −$1.09 | −$1.54 | −$1.01 | −$1.03 | −$1.16 | −$2.01 | — | — | — |
| Cash per share | $0.24 | $0.26 | $0.37 | $0.43 | $0.43 | $0.59 | $0.77 | — | — | — |
| Book value per share | −$6.03 | −$1.33 | −$0.89 | $1.05 | $1.05 | $1.15 | $1.86 | — | — | — |
| Tangible book value per share | −$6.41 | −$1.71 | −$1.27 | $0.65 | $0.48 | $0.31 | $0.11 | — | — | — |
| Capex per share | $0.01 | $0.05 | $0.23 | $0.06 | $0.05 | $0.05 | $0.02 | — | — | — |
| Debt per share | $7.95 | $3.50 | $3.34 | $1.42 | $1.58 | $0.80 | $0.37 | — | — | — |
| Shares outstanding | 36.2M | 36.2M | 36.1M | 34.3M | 24.1M | 16.4M | 7.8M | — | — | — |
| Change in shares outstanding | +0.2% | +0.2% | +5.2% | +42.3% | +46.8% | +109.7% | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | −120.1% | −104.6% | −132.6% | −168.9% | −149.5% | −147.1% | −167.9% |
| Return on invested capital (ROIC) | −38.0% | −46.6% | −44.6% | −47.4% | −49.9% | −101.0% | −256.9% | −678.6% | −344.3% | −452.7% |
| Return on assets (ROA) | −212.8% | −20.5% | −67.0% | −41.6% | −42.4% | −68.3% | −104.3% | −105.2% | −87.5% | −75.8% |
| Return on tangible assets | −275.3% | −26.0% | −81.6% | −39.2% | −41.3% | −86.1% | −166.4% | −135.9% | −207.0% | −253.6% |
| Free cash flow margin | −536.4% | −762.1% | — | −629.8% | −556.1% | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $288.0M | $126.5M | $120.4M | $48.8M | $38.0M | $13.2M | $2.9M | — | $0 | $803,000 |
| Cash & short-term investments | $8.7M | $9.3M | $13.5M | $14.9M | $10.3M | $9.6M | $6.0M | $8.2M | $5.1M | $5.7M |
| Net debt | $279.3M | $117.2M | $106.8M | $34.0M | $27.7M | $3.5M | −$3.2M | −$8.2M | −$5.1M | −$4.9M |
| Debt / equity | — | — | — | 1.35 | 1.50 | 0.70 | 0.20 | — | 0.00 | 0.08 |
| Debt / assets | 3.75 | 1.46 | 1.22 | 0.45 | 0.54 | 0.33 | 0.11 | — | 0.00 | 0.04 |
| Current ratio | 1.19 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 3.27 | 2.74 | 1.78 |
| Quick ratio | 1.19 | 0.23 | 1.16 | 1.09 | 3.74 | 1.70 | 1.36 | 3.27 | 2.74 | 1.95 |
| Interest coverage | -1.9 | -4.0 | -15.6 | — | -372.2 | -34.4 | -20.5 | — | — | — |
| Working capital | $1.7M | −$36.9M | $2.7M | $2.2M | $10.2M | $4.1M | $1.8M | $5.8M | $3.4M | $2.8M |
| Invested capital | $60.7M | $69.2M | $74.8M | $70.0M | $53.1M | $22.4M | $11.4M | $317,000 | $2.6M | $4.8M |
| Tangible asset value | −$232.3M | −$61.8M | −$45.8M | $22.3M | $11.7M | $5.1M | $847,000 | $5.5M | $2.8M | −$1.0M |
| Net current asset value | −$284.8M | −$123.1M | −$111.3M | −$44.8M | −$29.4M | −$9.8M | −$4.2M | $5.0M | $2.0M | −$2.1M |
| Graham net-net per share | −$7.90 | −$3.45 | −$3.17 | −$1.47 | −$1.38 | −$0.66 | −$0.62 | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $80,000 |
| Share buybacks (net) | — | — | $43,000 | $0 | $0 | $0 | $0 | $0 | $0 | $173,000 |
| Capex / revenue | 11.1% | 36.3% | 179.8% | 40.1% | 29.1% | 100.1% | 422.6% | — | 50.4% | 107.3% |
| Capex / depreciation | 0.35 | 1.42 | 8.38 | 2.48 | 1.12 | 0.74 | 0.10 | 0.03 | 0.16 | 0.76 |
| Stock-based compensation / revenue | 53.2% | 55.9% | 20.7% | 56.4% | 64.4% | 422.2% | 13,777.4% | — | 608.7% | 767.3% |
| R&D / revenue | 483.6% | 665.4% | 745.6% | 635.7% | 447.4% | 1,755.0% | 31,690.3% | — | 2,505.2% | 2,183.8% |
| SG&A / revenue | 253.0% | 254.8% | 257.2% | 135.0% | 185.1% | 967.9% | 29,887.1% | — | 6,600.0% | 3,235.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 45.3 | 144.9 | 479.3 | 381.7 | 144.8 | 248.8 | — | — | — | 105.3 |
| Days of inventory on hand | — | — | — | — | -32.4 | -14.2 | — | — | — | -612.3 |
| Days payables outstanding | 201.1 | 12.5 | 612.7 | 14.7 | 19.1 | 19.0 | 172.4 | 176.6 | 797.3 | 1,038.6 |
| Cash conversion cycle (days) | -155.8 | 132.4 | -133.4 | 367.0 | 93.3 | 215.6 | — | — | — | -1,545.6 |
| Receivables turnover | 8.07 | 2.52 | 0.76 | 0.96 | 2.52 | 1.47 | — | — | — | 3.47 |
| Payables turnover | 1.82 | 29.29 | 0.60 | 24.87 | 19.12 | 19.22 | 2.12 | 2.07 | 0.46 | 0.35 |
| Asset turnover | 0.06 | 0.06 | 0.04 | 0.06 | 0.08 | 0.03 | 0.00 | 0.00 | 0.01 | 0.01 |
| Average receivables | $608,000 | $2.1M | $5.9M | $5.8M | $1.8M | $561,000 | — | — | — | $75,000 |
| Average payables | $843,500 | $1.2M | $1.6M | $1.4M | $1.0M | $751,500 | $638,000 | $653,500 | $817,000 | $1.1M |
| Average inventory | — | — | — | — | −$1.8M | −$561,000 | — | — | — | −$619,000 |
| Intangibles / total assets | 17.9% | 15.9% | 14.0% | 12.7% | 19.7% | 34.8% | 54.0% | 25.0% | 44.3% | 59.2% |
Computed from ARMP's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ARMP valuation and financial ratios
Armata Pharmaceuticals earned a return on invested capital of −38.0% in fiscal 2025. It ended the year with $288.0 million of debt and $8.7 million in cash and short-term investments, net debt of $279.3 million.
See the ARMP income statement, the ARMP chart for price history, or the ARMP stock overview for the latest quote and news.
ARMP key metrics FAQ
What is Armata Pharmaceuticals's ROIC?
Armata Pharmaceuticals's return on invested capital was −38.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Armata Pharmaceuticals have?
Armata Pharmaceuticals had total debt of $288.0 million at the end of fiscal 2025.
What is Armata Pharmaceuticals's free cash flow yield?
Armata Pharmaceuticals generated -$26.3 million of free cash flow in fiscal 2025, a free cash flow yield of −11.6% on its market value at year-end ($227.6 million).
What is Armata Pharmaceuticals's current ratio?
Armata Pharmaceuticals's current ratio was 1.19 at the end of fiscal 2025: current assets were 1.19 times current liabilities.